Kind Minds Program -Family for Depression

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Imperial High School, Imperial, CA
Depression+3 More
Kind Minds Program - Behavioral
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

Rates of anxiety and depression in youth are substantial, causing a major unmet need for effective interventions. Participation in mindfulness interventions has been demonstrated to reduce anxiety and depressive symptoms among teenagers. Parents' participation in mindfulness interventions has also been shown to reduce their children's mental health symptoms. However, there is no available evidence regarding potential additional benefits for adolescents' mental health of having both the adolescent and their parent or caregiver learn and practice mindfulness simultaneously. This pilot intervention study aims to explore potential additive effects of parent/caregiver participation in a digitally-based, kindness-focused, coached mindfulness intervention program for adolescents that lasts 9 weeks. Participating parent/caregiver-child pairs (n = 30) will include one teenager between 12 and 17 years old with a current diagnosis of an anxiety or depressive disorder and one parent/caregiver. All adolescent participants will take part in the mindfulness intervention. Half of the parents/caregivers will be randomized to also take part in the mindfulness program. Outcomes will be compared between families in which only the teen participates in the mindfulness program and families in which the teen and parent/caregiver participate in the intervention. Adolescents and parents/caregivers will take part in evaluations before, in the middle of, and after the end of the mindfulness program, meaning that participation in the study will take a total of approximately 12 weeks. Pre, mid, and post evaluations will include online questionnaires. Pre and post evaluations will also include clinical interviews via phone or video conference. Evaluations will include measures of mental health diagnoses and symptoms, mood, interpersonal and family functioning, mindfulness, and perceptions of/satisfaction with the program. Participating adolescents and parents/caregivers will also fill out weekly brief questionnaires of anxiety and depressive symptoms. The primary outcome of interest is adolescent mental health, including anxiety and depressive symptoms.

Eligible Conditions

  • Depression
  • Child's Anxiety

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 12-14 weeks after baseline assessment

Week 14
Generalized Anxiety Disorder-7
Kiddie Schedule for Affective Disorders and Schizophrenia interview -anxiety and depressive disorder modules
Patient Health Questionnaire-9
SCARED -Screen for child anxiety and related emotional disorders

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Kind Minds Program -Teen Only
1 of 2
Kind Minds Program -Family
1 of 2
Active Control
Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: Kind Minds Program -Family · No Placebo Group · N/A

Kind Minds Program -Family
Behavioral
Experimental Group · 1 Intervention: Kind Minds Program · Intervention Types: Behavioral
Kind Minds Program -Teen Only
Behavioral
ActiveComparator Group · 1 Intervention: Kind Minds Program · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12-14 weeks after baseline assessment

Trial Background

Prof. Denise A. Chavira, PhD
Principal Investigator
University of California, Los Angeles
Closest Location: Imperial High School · Imperial, CA
N/AFirst Recorded Clinical Trial
1 TrialsResearching Depression
0 CompletedClinical Trials

Eligibility Criteria

Age < 18 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.